Chapter 880 (2/2)

In Australia, after reading a large number of inside information about the industry that ordinary people can never see, Simon realized that the wisest choice for the medical industry is to stand behind the scenes with the westero system. After all, in the eyes of ordinary people, there are countless operations that should go to hell in this field.

It's like an orphan drug monopoly.

The plan Simon and Janet talked about when they were in Australia was actually what the major pharmaceutical giants in the United States were doing later in their memory, even forming a trend.

As a result, the price of many rare disease drugs with small market demand has soared from a few dollars a box to several thousand dollars or even tens of thousands of dollars a box in just a few years.

If it is before the 1990s, this kind of thing is unlikely to happen.

At that time, there were still a large number of large pharmaceutical enterprises in the United States, and the competition was very fierce. Moreover, after the orphan drug act was introduced in the United States in 1983, at the beginning, the traditional pharmaceutical giants did not pay attention to this field. Basically, many small businesses were trying to overtake.

After the start-up small enterprises develop the corresponding drugs, because of the constraints of bargaining power, government regulation and even their own morality, the prices are very cheap when they first put them on the market.

After the 1990s, the integration of the U.S. medical industry was completed, and Rui Hui and other pharmaceutical oligarchs rose. At the same time, they finally noticed that orphan drug companies and patents scattered around the market like pearls began to purchase on a large scale. Then, according to their own industry influence, they quickly increased their prices by hundreds, thousands or even tens of thousands of times.

Different from those small enterprises, the oligarchs in the pharmaceutical industry not only have strong bargaining power and monopoly power, but also have a strong voice at all levels of government. They are completely fearless when they raise prices. They even ask the authorities to enact laws to relax the price control in this field on the grounds that excessive government intervention will affect the enthusiasm of pharmaceutical enterprises in the research and development of rare diseases System.

As a result, the field of orphan drugs, which once flourished, not only quickly changed from cheap drugs to sky high price drugs, but also greatly raised the market threshold under the monopoly of pharmaceutical oligarchs, and even deliberately pushed the U.S. government to raise the audit threshold of orphan drugs. As a result, when the orphan drugs act was just launched in the 1980s, the state of ”a hundred flowers blossom” soon ceased, and it just became the pharmaceutical giants Private land after the first profit share.

Later, many patients who could not afford the expensive orphan drugs launched large-scale lawsuits against the medical giants, and the results basically ended in failure.

So that, in the process of arranging the westero system to enter the medical industry, the sentence in Marx's ”capital” always appeared in Simon's mind.

Capital comes to the world with evil.

However, Simon didn't stay away from this field because it was ”boring” according to Janet.

The law of the jungle is a world where the fat is easily available, but we don't hunt for it. As a result, we will become weaker and weaker.In addition to the general layout, Simon also made some small-scale arrangements according to the materials he had seen and the information he had memorized during his stay in Australia.

Like a company in San Francisco called Gilead.

Gilead, founded in 1987, had achieved nothing until the beginning of 1996, basically nothing.

According to the current situation and the information in his memory, Simon roughly pieced together the development track of this company, which is known as ”apple” in the pharmaceutical industry.

The key to Gilead's success is actually one person.

Donald Rumsfeld.

The politician, who served as US Secretary of defense for two consecutive times in 1975 and 2001, is now a member of Gilead's board of directors.

Rumsfeld will be chairman of Gilead in 1997.

Then, in 2001, Rumsfeld left his post and began to serve as the Defense Secretary of the Bush administration. Gilead also began to take off and became the ”Apple company” in the pharmaceutical industry by relying on a series of drugs for the treatment of hepatitis C.

Through these veins, ordinary people can only see four words: benefit transmission.

It's just how to file a lawsuit. Most people obviously don't know.

Simon knows.

Gilead's most important step is not to acquire a pharmaceutical company that has developed a treatment for hepatitis C, but to successfully break through the U.S. health care system at a high price!

If anyone knows about Gilead's hepatitis C drugs, it will be found that the cost of a course of treatment of related drugs is nearly $80000, and some of them will be sold for $1000 per tablet. The average American can't afford such a high price.

Under normal circumstances, if Gilead maintains such a high price, it will only become a niche drug, and the treatment will be limited to the rich.

In this way, it is impossible to get too much revenue.

However, it's very unexpected that Gilead has miraculously entered the US health care system while maintaining the high price of its hepatitis C drugs.

Now, the huge price of $80000 for a course of treatment is basically paid by the U.S. government and insurance companies. As long as ordinary Americans have health insurance and get hepatitis C, they don't need to spend much money. The U.S. government and insurance companies pay for it.

On the surface, Americans think they will not suffer. However, where does the money from the US government and insurance companies come from?

It's not going to fall from the sky.

This seems to be very beneficial to patients, in fact, is the root cause of the abnormally high cost of medical care in the United States.

As for the interests involved, it is clear at a glance.

Now that the layout has been determined, Simon will certainly not let the company go, and plans to push a former defense secretary who is only a member of the board of directors to the position of chairman in advance.

Besides Gilead, Simon has not forgotten China.

There are mainly two aspects of the layout: Traditional Chinese medicine and health care products.

Simon plans to set up some start-ups in China to study the feasibility of mass production of traditional Chinese medicine. The accumulation of Chinese traditional medicine for thousands of years is actually a potential gold mine.

In addition, the most important thing is actually investment in the field of health care products.

It happens that there is a very good opportunity here.

A guy who built a building in Zhuhai will soon go bankrupt because of the rupture of the capital chain, which is a very suitable supporting object.